Jeffrey S.  Heier net worth and biography

Jeffrey Heier Biography and Net Worth

Chief Scientific Officer of Ocular Therapeutix

Jeffrey S. Heier, MD, is and will continue to serve as the Director of the Vitreoretinal Service and Director of Retina Research at Ophthalmic Consultants of Boston (OCB), one of the largest multi-specialty ophthalmology practices in the United States. Dr. Heier served as Co-President & Medical Director of OCB from 2016-2020. Dr. Heier is the Immediate Past President of the Retina Society and served as a member of the Executive Committee of the American Society of Retina Specialists from 2016 to February 2024. He is the Past President of the New England Ophthalmological Society and a member of the Macula Society. Dr. Heier is one of the leading retinal clinical researchers in the country for new treatments in exudative and non-exudative macular degeneration, diabetic macular edema, venous occlusive disease, vitreoretinal surgical techniques and instrumentation, and diagnostic imaging of the retina. He has served as one of the national or international lead investigators on numerous landmark clinical trial programs, including the Phase 3 trials of pegcetacoplan for advanced dry AMD, aflibercept and ranibizumab for neovascular AMD, and the dexamethasone implant for retinal venous occlusive disease. Dr. Heier serves as the chair of multiple scientific advisory boards and steering committees focusing on study design, outcomes analysis, and implementation of new agents into clinical practice. Dr. Heier has served as the Principal Investigator in more than 200 clinical trials. He lectures nationally and internationally, and has authored over 140 peer-reviewed works. Dr. Heier has received the Life Achievement Honor Award, The Secretariat Award, The Senior Achievement Award, and the Honor Award from the American Academy of Ophthalmology, and The Presidential Honor Award, The Senior Honor Award, and the Honor Award from the American Society of Retina Specialists. Dr. Heier was selected as a charter inductee of the Retina Hall of Fame in 2017. Dr. Heier received his medical degree from Boston University, completed an internship and residency at Fitzsimons Army Medical Center, and a vitreoretinal fellowship at Ophthalmic Consultants of Boston/Tufts School of Medicine. He served as a physician in a Combat Support Hospital in the Persian Gulf War, where he was awarded a Bronze Star.

What is Jeffrey S. Heier's net worth?

The estimated net worth of Jeffrey S. Heier is at least $1.97 million as of November 25th, 2024. Dr. Heier owns 269,059 shares of Ocular Therapeutix stock worth more than $1,974,893 as of April 3rd. This net worth estimate does not reflect any other investments that Dr. Heier may own. Additionally, Dr. Heier receives a salary of $86,160.00 as Chief Scientific Officer at Ocular Therapeutix. Learn More about Jeffrey S. Heier's net worth.

How old is Jeffrey S. Heier?

Dr. Heier is currently 63 years old. There are 3 older executives and no younger executives at Ocular Therapeutix. Learn More on Jeffrey S. Heier's age.

What is Jeffrey S. Heier's salary?

As the Chief Scientific Officer of Ocular Therapeutix, Inc., Dr. Heier earns $86,160.00 per year. Learn More on Jeffrey S. Heier's salary.

How do I contact Jeffrey S. Heier?

The corporate mailing address for Dr. Heier and other Ocular Therapeutix executives is 15 CROSBY DRIVE, BEDFORD MA, 01730. Ocular Therapeutix can also be reached via phone at (781) 357-4000 and via email at chris.brinzey@westwicke.com. Learn More on Jeffrey S. Heier's contact information.

Has Jeffrey S. Heier been buying or selling shares of Ocular Therapeutix?

Jeffrey S. Heier has not been actively trading shares of Ocular Therapeutix during the past quarter. Most recently, Jeffrey S. Heier sold 2,948 shares of the business's stock in a transaction on Monday, November 25th. The shares were sold at an average price of $9.01, for a transaction totalling $26,561.48. Following the completion of the sale, the insider now directly owns 269,059 shares of the company's stock, valued at $2,424,221.59. Learn More on Jeffrey S. Heier's trading history.

Who are Ocular Therapeutix's active insiders?

Ocular Therapeutix's insider roster includes Pravin Dugel (Executive Chairman, President and CEO), Jeffrey Heier (Chief Scientific Officer), Richard Lindstrom (Director), Antony Mattessich (CEO), Sanjay Nayak (Insider), and Donald Notman (Chief Financial Officer and Chief Operating Officer). Learn More on Ocular Therapeutix's active insiders.

Are insiders buying or selling shares of Ocular Therapeutix?

During the last year, insiders at the biopharmaceutical company sold shares 6 times. They sold a total of 45,949 shares worth more than $340,138.76. The most recent insider tranaction occured on February, 24th when insider Pravin Dugel sold 21,475 shares worth more than $147,533.25. Insiders at Ocular Therapeutix own 3.5% of the company. Learn More about insider trades at Ocular Therapeutix.

Information on this page was last updated on 2/24/2025.

Jeffrey S. Heier Insider Trading History at Ocular Therapeutix

See Full Table

Jeffrey S. Heier Buying and Selling Activity at Ocular Therapeutix

This chart shows Jeffrey S Heier's buying and selling at Ocular Therapeutix by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$20k-$10k$0$10k$20kTotal Insider BuyingTotal Insider Selling

Ocular Therapeutix Company Overview

Ocular Therapeutix logo
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
Read More

Today's Range

Now: $7.34
Low: $6.42
High: $7.34

50 Day Range

MA: $7.47
Low: $5.93
High: $8.51

2 Week Range

Now: $7.34
Low: $4.06
High: $11.78

Volume

1,867,225 shs

Average Volume

1,548,497 shs

Market Capitalization

$1.17 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.49